Showing: 1 - 2 of 2 RESULTS

Brazil coronavirus vaccine trials: Volunteers counter anti-vaxxers

“A two-front war,” she said.

It’s one reason the 33-year-old physician is participating in clinical trials for an experimental vaccine by the Chinese manufacturer Sinovac. It might be a chance to inoculate herself against a disease that terrified her. But it was also an opening to align herself with evidence and logic — rather than the doubts and medical falsehoods she saw proliferating across Brazil.

Brazil has long been recognized as one of the vaccine-friendliest countries in the world. It has universal health care, a strong public medical system, a population that has trusted vaccines and a history of carrying out massive and logistically challenging immunization campaigns. Yellow fever, measles and other pathogens have all been brought into submission.

That record, and a relentless coronavirus outbreak that has killed more than 150,000 Brazilians and infected more than 5 million, have made Brazil an inviting testing ground in the global race for a vaccine. Four of the leading vaccine candidates are being studied in the country. That’s as many as anywhere in the world. Tens of thousands of Brazilians have received trial vaccines to ensure their safety and efficacy before they’re approved for broader use.

But Brazil’s vaunted culture of vaccination is now coming under strain. The uncertainties unleashed by the coronavirus pandemic — amplified by social media and echoed by a polarizing president who has flouted health guidelines and promoted miracle cures — has rapidly eroded trust painstakingly built over decades.

In June last year, 97 percent of Brazilians said they believed in the importance of vaccinating children, according to an international a survey by the Wellcome Global Monitor. That figure was higher than the global average of 92 percent and higher than regional neighbors. But months into the country’s coronavirus outbreak, the number of Brazilians who say they would certainly get a coronavirus vaccine has fallen to 76 percent.

Bolsonaro, rather than rallying support for a vaccine, has undercut it.

“No one can force anyone to take a vaccine,” he has said.

Falling support for a vaccine, even as researchers plow ahead with trials, has worried scientists who say Brazil is at risk of losing faith in science at the most critical time. Many Brazilians are returning to old routines while the country is still in the full grip of the virus. It’s killing hundreds, sometimes more than 1,000, every day. Tens of thousands more fall ill.

“This is a decisive moment,” said João Henrique Rafael Junior, a researcher at the University of São Paulo. In a survey published last month, he found the number of social media posts in Brazil spreading doubt and misinformation about vaccines has nearly quadrupled since the beginning of the pandemic.

“We need to reverse the curve,” he said. “We are going through the worst health crisis in a century, and we need to employ all of our strength. The time is now. Actually, the time was yesterday.”

Natália Pasternak Taschner, a microbiologist, warned the conditions could lead to disaster.

“We are witnessing something

Russian COVID-19 vaccine trials have yet to start in Brazil, lagging rivals

BRASILIA (Reuters) – Testing of Russia’s “Sputnik-V” COVID-19 vaccine has not begun in Brazil, while its British and Chinese rivals have already begun to file partial results from clinical Phase III trials, the Brazilian health regulator Anvisa said on Tuesday.

Brazil’s Paraná and Bahia states, which have testing and production or distribution agreements for the Russian vaccine, have not yet filed requests for clinical trials in Brazil, a spokeswoman for Anvisa said.

“There have been numerous meetings, physical and online, with no documents on the Russian vaccine materializing yet,” she told Reuters.

The Russian Direct Investment Fund (RDIF), which is marketing the Sputnik, touted by Russia as the world’s first registered vaccine, did not immediately reply to a request for comment.

Meanwhile, trials for the vaccine developed by Oxford University and AstraZeneca Plc , and another potential vaccine by China’s Sinovac Biotech Ltd are being conducted at a dozen sites and initial data sent in to Anvisa.

“This is still not a formal request for registration of these vaccines. We will only consider that when all the documents have been filed,” the spokeswoman told Reuters.

To speed up the process, Anvisa last week started a process of continuous filing of paperwork and initial results so that they can be studied simultaneously.

With the second most deadly coronavirus outbreak after the United States, Brazil has become a key testing ground for the vaccines under development.

Anvisa has authorized trials in Brazil for four vaccines, including those under development by Pfizer Inc in partnership with BioNTech and Johnson & Johnson’s pharmaceutical subsidiary Janssen.

Brazil has had almost 5 million confirmed cases of coronavirus and the death toll reached 146,675 on Monday, the Health Ministry said.

(Reporting by Anthony Boadle; Editing by Lisa Shumaker)

Source Article